O Y, Orii T: Japan Elaprase Treatment (JET) study: idursulfase enzyme

O Y, Orii T: Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 2010, 99(1):18-25. Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE: Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011, 34(1):203-208. Miebach E: Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther 2009, 47(Suppl 1):S100-106. Burton BK, Wiesman C, Paras A, Kim K, Katz R: Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Mol Genet Metab 2009, 97(3):234-236. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A: Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006, 15(6):330-333. Hughes DA, Mlilligan A, Mehta A: Home therapy for lysosomal storage disorders. Br J Nurs 2007, 16(22):1386-1389. Burton BK, Guffon N, Roberts J, van de Ploeg AT, Jones SA: Home treatment with intravenous enzyme replacement therapy with43. 44.45.46.47.48.49.50.51.52.53.54.55.56.57. 58.59.idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab 2010, 101(2-3):123-129. Little C, Gould R, Hendriksz C: The management of children with Hunter syndrome - a case study. Br J Nurs 2009, 18(5):321-322. Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE: Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis 2008, 31(6):733-737. Muenzer J, Beck M, Giugliani 2-Bromo-4-fluoro-5-methylbenzoic acid R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, Vellodi A, Wraith JE: Idursulfase treatment of Hunter syndrome in children under 6 years old: results from the Hunter Outcome Survey. Genet Med 2011, 13(2):102-109. Vellodi A, Wraith JE, Cleary MA, Ramaswami U, Lavery C, Jessop E: 6-(Thiophen-3-yl)pyridin-3-amine Guidelines for the investigation and management of PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/4155310 mucopolysaccharidosis type II. Department of Health National PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 Specialist Commissioning Group (NSCAG) 2007 [http://www.dh.gov.uk/ prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/ digitalasset/dh_073340.pdf]. Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, et al: Multidisciplinary management of Hunter syndrome. Pediatrics 2009, 124(6):e1228-1239. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, NaudSaudreau C, Rolland MO, Debre M, Chaussain JL, Griscelli C, et al: Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990, 322(26):1860-1866. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DC, Lucas CF, Rogers TR, Benson PF, et al: Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981, 2(8249):709-712. Krivit W, Pierpont ME, Ayaz K, Tsai M, Ramsay NK, Kersey JH, Weisdorf S, Sibley R, Snover D, McGovern MM, et al: Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med 1984, 311(25):1606-1611. Krivit W, Shapiro E, Kennedy W, Lipton M, Lockman L, Smith S, Summers CG, Wenger DA, Tsai MY, Ramsay NK, et al: Treatment of late infantile.